Europe Cardiometabolic Diseases Market

Market Introduction

The cardiometabolic disease is characterized by a group of abnormalities and symptoms that raise the risk of individuals developing cardiovascular disease. Hypertension, obesity, insulin resistance, dyslipidemia, poor cholesterol profile (LDL), and glucose tolerance are some of the symptoms. Individuals suffering from cardiometabolic syndrome are prone to several other life-threatening diseases such as type 2 diabetes, stroke, coronary artery disease (CAD), cardiovascular disease (CVD), and many others.

Moreover, the increasing prevalence of cardiometabolic diseases is expected to bolster the market growth during the forecast period. However, underdiagnosis of CVDs in low- and middle-income countries (LMICs) limits the growth of the Europe cardiometabolic diseases market.

In Europe, the COVID-19 pandemic has significant implications on the cardiovascular care of patients. Those living with pre-existing cardiovascular diseases have an increased risk of health deterioration and death on contracting COVID-19. Prevention, diagnosis, and treatment services for CVDs have been severely disrupted since the COVID-19 pandemic. According to MedTech Europe, around 95% of all COVID-19 deaths had at least one underlying condition, with cardiovascular disease being the leading comorbidity (65%). Also, around 50% decrease in the number of people visiting at hospitals and other health care facilities with symptoms of heart attacks or stroke, creating a significant backlog of patients with severe health conditions. Also, a reduction in emergency department attendances for cardiac presentation compared with the previous year dropped by between 31% and 88% after a lockdown in the UK, negatively impacting the market growth. The pandemic has significantly impacted the market in the short term; however, the market will grow at a moderate pace in the forecast period.

Europe Cardiometabolic Diseases Strategic Insights

Strategic insights for the Europe Cardiometabolic Diseases provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Cardiometabolic Diseases Report Scope

Europe Cardiometabolic Diseases Regional Insights

The geographic scope of the Europe Cardiometabolic Diseases refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Europe cardiometabolic diseases market is projected to reach US$ 33,963.6 million by 2028 from US$ 26,717.5 million in 2021; it is anticipated to grow at a CAGR of 3.5% from 2021 to 2028. An integrated risk tool (IRT), created by Genomics plc, will be used to estimate each patient's risk of developing a CVD within the next 10 years. The company has claimed that if the IRT is applied to everybody aged between 40 and 60 in the UK, it could identify more than 650,000 people at high risk of CVDs, missed by current screening. Apart from this, recent advances on the Internet of Things (IoT), cloud computing, and artificial intelligence (AI) have significantly improved the conventional healthcare system. In August 2021, South Ural State University (SUSU) scientists have developed a model for more effective diagnosis of CVDs and diabetes, using AI and IoT. Moreover, the integration of AI is further offering lucrative opportunities for the growth of the cardiometabolic disease market and is expected to continue supporting this market over the forecast period. In June 2021, The ACC and GE Healthcare collaborated through the support of and participation in ACC's Applied Health Innovation Consortium (AHIC) to build a roadmap for AI and digital technology in cardiology and develop new strategies for improved health outcomes.

Key Market Segments

In terms of type, the cardiovascular disease segment accounted for the largest share of the Europe cardiometabolic diseases market in 2020. In terms of treatment, the ACE inhibitors segment accounted for the largest share of the Europe cardiometabolic diseases market in 2020. In terms of dosage, the tablet segment accounted for the largest share of the Europe cardiometabolic diseases market in 2020. In terms of route of administration, the oral segment accounted for the largest share of the Europe cardiometabolic diseases market in 2020. In terms of end user, the hospital segment accounted for the largest share of the Europe cardiometabolic diseases market in 2020. Further, based on distribution channel, the hospital pharmacy segment held the largest market share in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the cardiometabolic diseases market in Europe are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Eli Lilly and Company., Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S, AstraZeneca, Alnylam Pharmaceuticals, Inc., and Kowa Company, Ltd.

Reasons to Buy Report

• To understand the Europe cardiometabolic diseases market landscape and identify market segments that are likely to guarantee a strong return
• To comprehend the ever-changing market landscape and stay ahead in competition
• To efficiently plan merger and acquisition, and partnership deals in the Europe cardiometabolic diseases market by identifying segments with the most promising probable sales
• To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
• To obtain market revenue forecast of the Europe cardiometabolic diseases market based on various segments for the period 2021–2028

EUROPE CARDIOMETABOLIC DISEASES MARKET SEGMENTATION

By

• Cardiovascular disease (CVD)
• Type 2 diabetes
• Hypertension
• Obesity 

By Treatment

• ACE inhibitors
• Diuretics
• Glucophage
• Others 

By Dosage

• Tablet
• Injection 

By Route of Administration

• Oral
• Intravenous 

By End Users

• Hospital
• Clinic
• Homecare settings 

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Country

• Europe
• Germany
•  UK
•  France
• Spain
• Italy
• Rest of Europe

Companies Mentioned

• Eli Lilly and Company

  .

     
• Bayer AG                         
• Novartis AG                   
• Boehringer Ingelheim International Gmbh
• Novo Nordisk A/S       
• AstraZeneca                  
• Alnylam Pharmaceuticals, Inc.

• Kowa Company, Ltd.